Buy this article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Source:

Journal of Infusion Nursing

June 2013, Volume 36 Number 3 , p 172 - 178

Author

  • Keith Dawson DNP, MS, RN, NEA-BC

Abstract

The majority of follicular non-Hodgkinʼs lymphoma patients in the United States receive an initial treatment strategy that includes the infusion of rituximab. Data from a phase III multicenter clinical trial led to the 2012 US Food and Drug Administration approval of a 90-minute infusion of rituximab (Rituxan) starting at Cycle 2 for patients with non-Hodgkinʼs lymphoma who did not experience a Grade 3 or 4 infusion-related adverse event during Cycle 1. A review of literature was undertaken to identify existing evidence regarding both the safety of rituximab faster infusion and its impact on nursing practice. The aim of this article is to stimulate discussion and lead to implementation of evidence-based nursing practices to improve the delivery of patient care.

To continue reading, buy this article for just $7.95.

Have a coupon or promotional code? Enter it here: